JKHY vs URGN · P/E 30, rev $2.54B vs rev $109.8M
Jack Henry & Associates Inc (JKHY) versus UroGen Pharma Ltd (URGN) — a side-by-side from cached financials, not a winner call.
Jack Henry & Associates Inc (JKHY) is a information technology services company listed on US.
UroGen Pharma Ltd (URGN) is a biotechnology company listed on NASDAQ.
Latest reported JKHY revenue for 2026-06-30 was $2.54B. Net income was $502.8M. Revenue was up 7.1% from 2025-06-30 to 2026-06-30. JKHY currently screens at market cap $12.76B and trailing P/E 29.8.
Latest reported URGN revenue for 2025-12-31 was $109.8M. Net income was -$153.5M. URGN currently screens at market cap $1.61B.
JKHY currently screens at market cap $12.76B and trailing P/E 29.8. URGN currently screens at market cap $1.61B.
Not investment advice. Open the JKHY and URGN stock pages for the full models.
Not investment advice.